The Healthy Aging Company

DEVELOPING GAME CHANGER THERAPIES FOR
Neurodegenerative diseases with potential for other age-related diseases

Welcome to THAC – The Healthy Aging Company

At THAC, we are dedicated to revolutionizing the treatment of diabetes and its neurologic and neurodegenerative complications and other age-related conditions through cutting-edge innovation. 

Our Mission

Our mission is to develop game-changing therapies that address unmet medical needs and improve the lives of millions worldwide.

The Problem

Tackling the Global Epidemic of Diabetes and Age-Related Diseases

As society ages, age-related diseases are reaching epidemic proportions, posing immense challenges to healthcare systems and economies worldwide:

90%

of older adults have at least one chronic condition, nearly 80% have two or more

Global Health Crisis

Conditions such as cardiovascular disease, obesity, diabetes, and Alzheimer’s are now global health crises

80%

Age related diseases represent 80% of the US Medicare budget

$30 trillion

Age-related diseases are projected to cost over $30 trillion over the next 20 years

Diabetes and Diabetes-associated complications are major drivers of age-related diseases.
Despite major improvement of the treatment of Diabetes type II with GLP1 Receptor Agonists, diabetic neuropathy and diabetes-associated cognitive disorders and Alzheimer’s disease are still major unmet medical needs.

« At THAC, we are committed to addressing these challenges head-on with innovative therapies designed to improve lives and transform healthcare for a healthier, more sustainable future ».

Leveraging our expertise in biopharmaceutical research, we focus on: 

Type 2 Diabetes Mellitus (T2DM) and associated complications

Diabetic Neuropathy

Cognitive disorders and Alzheimer’s Disease

Other conditions associated with aging 

Our Solution: ALF-5755 – A Breakthrough Therapy

At THAC, we are leading the charge with ALF-5755, an innovative therapy designed to directly target the root causes of age-related diseases, offering hope for millions:

  • Directly targets insulin resistance – addressing the core driver of Type 2 Diabetes and metabolic disorders.
  • Anti-inflammatory action – reduces systemic inflammation associated with chronic conditions.
  • Reduces fat mass and triglycerides – supporting healthier weight and metabolic balance.
  • Stimulates glucose uptake in muscle – improving glycemic control and energy utilization.
  • Reduces diabetic neuropathy – alleviating complications like diabetic foot wounds and preventing amputations.
  • Limits sarcopenia – preserving muscle mass and strength in aging individuals.
  • Improves cognition – targeting neurodegeneration to combat Alzheimer’s disease.
  • Directly targets insulin resistance – addressing the core driver of Type 2 Diabetes and metabolic disorders.

With ALF-5755, we are transforming the way age-related diseases are treated, improving patient outcomes, and redefining the future of healthcare.

THAC is a resident at The Institute of Diabetes,
Paris (France)
and at the University of South Florida (US)

Explore Our Blog

Contact us

♦ Our location in France
Cochin Hospital – APHP
Incubateur Paris Biotech Santé
24 Boulevard du Faubourg Saint Jacques
75014 Paris, France
 
♦ Our location in the United States
University of South Florida
USF Connect Incubator
3702 Spectrum Blvd.
Tampa, FL 33612, USA